Jennifer Johnston is the creative force behind NysnoBio, guiding the business and scientific focus of the company as CEO with more than 20 years of experience in the biopharmaceutical industry, including 13 years leading neurodegenerative disease research at Elan Pharmaceuticals. At Elan, Dr. Johnston took multiple molecules for Parkinson’s disease (PD) from initial discovery to candidate selection. She cofounded NysnoBio to focus on novel PD therapeutics. Studying ubiquitin’s role in neurodegeneration has been a central focus of her work, from her PhD at Dartmouth to her work on the first E3 ligase at Caltech to her discovery of aggresomes at Stanford. Dr. Johnston holds more than ten patents and has been on the SAB of the Michael J. Fox Foundation for more than 18 years. She has also been a member of the USA Track & Field 100K Team, earning bronze and silver medals in the national championships.
Associated Grants
-
Neural Network Imaging Analysis in Parkinson’s Disease Associated with Parkin Mutation
2022
-
Efficacy of PRKN Gene Delivery toward Mitigation of Alpha-synuclein-induced Degeneration
2021
-
In Vivo Approach to Elucidate the Pathobiology of Parkinson’s-associated Genes Using Human Diseased Neurons
2020
-